Fasenra
Payments companies reported to CMS as associated with Fasenra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fasenra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fasenra
These are the largest totals companies reported as associated with Fasenra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Marcus | Brooklyn, NY | Pediatric Allergy/Immunology | $250,407.43 |
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $248,339.23 |
| Rohit Katial | Denver, CO | Allergy & Immunology | $245,668.17 |
| Keith Harris | Port Jefferson Station, NY | Pulmonary Disease | $198,773.95 |
| Joseph Forester | Cullman, AL | Allergy & Immunology | $196,001.53 |
| Michael Wechsler | Denver, CO | Pulmonary Disease | $174,827.00 |
| Joel Hartman | Winston Salem, NC | Allergy & Immunology | $174,821.42 |
| Lawrence Dubuske | Washington, DC | Allergy & Immunology (Internal Medicine) | $173,656.17 |
| Hassan Nasir | West Branch, MI | Allergy & Immunology | $162,831.31 |
| Ali El Atat | Brooklyn, NY | Pulmonary Disease | $129,197.90 |
Prescribed Fasenra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.